Company intelligence / Profile preview

REGEN Bio Global

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

REGEN Bio Global is a biotechnology company focused on the development of regenerative medicine and immunotherapy treatments. The company leverages advanced cell therapy and gene silencing technologies to address complex conditions such as cancer, autoimmune disorders, and chronic metabolic diseases. Their research primarily centers on modulating the immune system through targets like NR2F6 and IDO to enhance the body's natural ability to fight disease. REGEN Bio Global aims to bridge the gap between laboratory discovery and clinical application through strategic global partnerships and a robust intellectual property portfolio.

Therapeutic areas: OncologyEndocrinologyImmunologyNeurology
Modalities: Cell therapyExosome-based therapyGene therapySmall molecule
Industry: Biotech

Partnerships

Regen BioPharma

Beyond the preview

Go deeper on REGEN Bio Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEN Bio Global.

Explore the full profile